Edition:
United States

Almirall SA (ALM.MC)

ALM.MC on Madrid SE C.A.T.S.

11.35EUR
25 May 2018
Change (% chg)

€-0.15 (-1.30%)
Prev Close
€11.50
Open
€11.46
Day's High
€11.53
Day's Low
€11.22
Volume
339,953
Avg. Vol
419,373
52-wk High
€15.80
52-wk Low
€7.28

Chart for

About

Almirall SA is a Spain-based company principally engaged in the pharmaceuticals manufacture. The Company focuses on development and marketing of drugs applied in various therapeutic areas, such as nervous system, gastrointestinal, dermatological, respiratory system, antiinfectives, as well as antineoplastic and immunomodulating... (more)

Overall

Beta: 0.31
Market Cap(Mil.): €1,962.99
Shares Outstanding(Mil.): 172.95
Dividend: 0.18
Yield (%): 1.62

Financials

  ALM.MC Industry Sector
P/E (TTM): -- 29.19 33.30
EPS (TTM): -1.69 -- --
ROI: -14.02 13.53 13.04
ROE: -21.75 15.25 14.90

BRIEF-Almirall Sees 20 Pct EBITDA Growth In 2018

* FY EBITDA 142.2 MILLION EUROS VERSUS 227.6 MILLION EUROS YEAR AGO

Feb 23 2018

BRIEF-Almirall FY Net Result Turns To Loss Of 304 Million Euros

* FY NET LOSS 304.0 MILLION EUROS VERSUS PROFIT OF 75.5 MILLION EUROS YEAR AGO

Feb 23 2018

BRIEF-Almirall Signs Distribution Agreement With AstraZeneca For Crestor And Provisacor In Spain

* EXECUTES LICENSE AND SUPPLY AGREEMENT WITH ASTRAZENECA FOR CRESTOR AND PROVISACOR (ROSUVASTATIN)

Dec 22 2017

BRIEF-Almirall And Athenex Announces Partnership For Treatment Of Actinic Keratosis

* ALMIRALL AND ATHENEX ANNOUNCE STRATEGIC PARTNERSHIP FOR THE TREATMENT OF ACTINIC KERATOSIS

Dec 11 2017

BRIEF-Almirall Announces Positive Top-Line Results From ASCENT Trial For Tudorza‍​

* ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE IV ASCENT TRIAL FOR TUDORZA‍​

Dec 04 2017

Earnings vs. Estimates